Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05927532 · ClinicalTrials.gov registry record · NA
Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study
A NA study of End Stage Renal Failure on Dialysis, sponsored by Mozarc Medical US.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT05927532 is a NA study of End Stage Renal Failure on Dialysis that has completed, run by Mozarc Medical US. The registered enrollment target is 40 participants, below the 270-participant average among 3 other End Stage Renal Failure on Dialysis trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05927532, a NA study of End Stage Renal Failure on Dialysis, has completed, sponsored by Mozarc Medical US.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
Conditions Studied
Interventions
- DEVICE Argyle Safety Fistula Cannula with Anti-Reflux Valve
Study Locations (3)
Connecticut
- DaVita Hartford - Hartford
Georgia
- DaVita Columbus - Columbus
Virginia
- DaVita Norfolk - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-10 |
| Est. Completion | 2024-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05927532
The ClinicalTrials.gov registry entry for NCT05927532 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 3 other End Stage Renal Failure on Dialysis trials with a reported enrollment target (85% lower). The listed sponsor is Mozarc Medical US, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Failure on Dialysis appearing as the primary indexed condition, and to 1 intervention - of which Argyle Safety Fistula Cannula with Anti-Reflux Valve is the first listed.
NCT05927532 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Georgia, Virginia.
Frequently Asked Questions
What is clinical trial NCT05927532 about?
NCT05927532 is a clinical study titled "Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study". The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
What is the current status of trial NCT05927532?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2024-03-10. Estimated completion is 2024-12-15.
What conditions does trial NCT05927532 study?
This clinical trial studies the following conditions: End Stage Renal Failure on Dialysis.
What interventions are being tested in trial NCT05927532?
The interventions under investigation include: Argyle Safety Fistula Cannula with Anti-Reflux Valve (DEVICE).
Who is sponsoring clinical trial NCT05927532?
This trial is sponsored by Mozarc Medical US, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05927532 being conducted?
This trial has 3 study locations across Connecticut, Georgia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Failure on Dialysis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.